![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.560, 2008-01, pp. : 9-9
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Sunitinib cost effective for renal cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 532, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Sunitinib soars ahead in renal cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 580, 2009-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Sunitinib surpasses standard therapy for metastatic renal cancer
Inpharma, Vol. 1, Iss. 1544, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
First-line sunitinib cost-effective alternative to interferon-α in renal cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 561, 2008-01 ,pp. :